Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...
As Q1 earnings roll in, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least ...
A subsidiary of Indian drugmaker Hetero Group mistakenly packaged two types of antidepressants in packs of sertraline, ...
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier ...
Candid Therapeutics follows closely behind Neurona Therapeutics, which UCB acquired in mid-April in a potential $1.15 billion ...
Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than ...
Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Amid disruption to the outsourced fill/finish market, PCI is investing $100 million to more than double the capacity to fill ...
In its latest biopharma pipeline report, Deloitte warned that the growing importance of a small pool of potential ...
The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.
The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results